Abstract:We recently read the article by Tian et al with great interest.1 In their research, the authors compared the prognosis of patients with gastric and gastroesophageal junction adenocarcinoma who received perioperative chemoradiotherapy (PCRT) with those who received perioperative chemotherapy (POC) alone. The authors found that the addition of preoperative radiotherapy to POC appears to be associated with an increased risk of death in both the gastric and gastroesophageal junction adenocarcinoma subgroups. However, by reviewing previous studies and conducting an external validation based on the Surveillance, Epidemiology, and End Results (SEER) database, we found some contradicting results. Thus, we believe more caution should be exercised regarding any conclusions that additional radiotherapy increased the risk of death. In the majority of previous studies, a similar prognosis was demonstrated between the PCRT and the POC groups,2-4 a finding that contradicts the results published by Tian et al.1 Furthermore, if we focused on the patient with a T3 to T4 tumor, PCRT might have a positive influence on survival. For example, Stahl et al reported that in the Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET) trial (in which only patients with T3-T4 tumors were included),5 the PCRT group had a significantly improved progression-free survival (hazard ratio [HR], 0.37; P = .01) and the overall survival (OS) also demonstrated a positive trend (HR, 0.65; P = .055). Trying to investigate the result further, we conducted a validation study based on the SEER database, which also is nationwide. We included patients from 2004 through 2014 in the SEER database using the criteria of Tian et al.1 A total of 2201 patients finally were selected in our research, 934 of whom received PCRT and surgery, 336 of whom received POC, and 931 of whom underwent surgery alone. Pairwise 1:1 propensity score matching was performed to compare the survival outcomes among the 3 groups. It was shown that both the PCRT and the POC groups experienced a survival benefit compared with the group treated with surgery alone. However, there was no statistically significant difference noted with regard to the overall survival or cancer-specific survival between the PCRT and the POC groups. We also conducted a subgroup analysis using Cox regression. Within the population of patients with T3 to T4 disease, the PCRT group was found to have significantly improved prognosis compared with the surgery-alone group (HR, 0.44; 95% CI, 0.34-0.58 [P < .001]). Compared with the POC group, the result indicated a survival advantage for PCRT (HR, 0.74; 95% CI, 0.54-1.02 [P = .07]), although statistical significance was not achieved. In addition, it was shown that the PCRT group had a significantly better prognosis than both the POC and surgery-alone groups among patients with T3 to T4 disease and with positive lymph nodes (HRs of 0.65 and 0.44, respectively [P = .02 and P < .001, respectively]). Based on the above evidence, although the contradiction between the study by Tian et al1 and the previous ones remains difficult to explain, it is rational to assume that patients with advanced disease benefit more from radiotherapy. Thus, instead of concluding that radiotherapy may increase the risk, we believe a subgroup analysis is needed. In addition, the description of the tumor stage and patients' characteristics after propensity score matching may facilitate further discussion. No specific funding was disclosed. The authors made no disclosures.

Organ Preserving Strategies is an Alternative for the Management of Pediatric Patients with Solid Pseudopapillary Neoplasm.

Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreatic cancer

Long-term Outcomes and Prognostic Factors for Locally-Advanced Pancreatic Cancer Patients Treated with Intraoperative Radiation Therapy

Comparison of Therapeutic Effects of Chemoradiation, 125I Seed Implantation Combined with Chemotherapy and Chemotherapy Alone in Locally Advanced Pancreatic Cancer

Comparison of Surgeries Plus Perioperative and Postoperative Chemotherapies in Chinese Pn2 Patients with Non-Small Cell Lung Cancer: A Real-World Observational Study.

Long-term Results of Intraoperative Electron Beam Radiation Therapy for Nonmetastatic Locally Advanced Pancreatic Cancer

Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis

Value of Intraoperative Radiotherapy in the Treatment of Locally Advanced Pancreatic Cancer

Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer

Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer

Incorporating stereotactic body radiation therapy for inoperable pancreatic cancer.

Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation

Retrospective study on laparoscopic surgery combined with intraoperative radiotherapy in treatment of locally advanced rectal cancerc

Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma

Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database

Irreversible electroporation followed by chemotherapy vs. chemotherapy alone for locally advanced pancreatic cancer: A large cohort propensity score analysis.

Intra-operative radiation for pancreatic cancer: Initial experience at the Hadassah Medical Center.

IORT and Regional Chemotherapy in Patients with Locally Advanced Pancreatic Carcinoma

Intraoperative Radiotherapy for Borderline Resectable Pancreatic Cancer: A Retrospective Analysis

Patients with Gastroesophageal Junction Adenocarcinomas of an Advanced Stage May Benefit from Perioperative Chemoradiotherapy: A Validation Based on the Surveillance, Epidemiology, and End Results Database

Dosimetric and clinical toxicity comparison of critical organ preservation with three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and RapidArc for the treatment of locally advanced cancer of the pancreatic head.